Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LABA advisory committee (again)

Executive Summary

The safety of long-acting beta-2 agonists like GlaxoSmithKline's Serevent Diskus (salmeterol) and Novartis' Foradil (formoterol), as well as affected combination products such as GSK's Advair (fluticasone/salmeterol) and AstraZeneca's Symbicort (budesonide/formoterol fumarate), will be discussed at a two-day joint meeting of FDA's Pulmonary-Allergy Drugs, Drug Safety and Risk Management, and Pediatric Advisory Committees Dec. 10-11. This will be the third committee review of the class, continuing FDA's inquiry into the benefits and risks of the LABA class for treatment of asthma in adults and children in light of an observed increased risk of asthma-related deaths
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS050269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel